BNT3212 + BNT327

BNT3212 + BNT327 is a combination of two investigational agents developed by BioNTech SE for the treatment of advanced solid tumors. BNT327 is a bispecific monoclonal antibody that targets *programmed death-ligand 1 (PD-L1)* and *vascular endothelial growth factor A (VEGF-A)*, aiming to inhibit both immune checkpoint signaling and angiogenesis in tumors, thereby enhancing immune-mediated antitumor activity and reducing tumor vascularization[2][7][9]. BNT3212 is an additionally unidentified investigational agent being evaluated as monotherapy or in combination with BNT327; the mechanism and precise target of BNT3212 have not been disclosed publicly in the available literature[1]. The combination is currently undergoing first-in-human studies focused on safety, pharmacokinetics, immunogenicity, and early efficacy in adults with advanced solid tumors who have exhausted other treatments[1].